Organogenesis (NASDAQ:ORGO) Issues Earnings Results, Beats Estimates By $0.01 EPS

Organogenesis (NASDAQ:ORGO - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01, Zacks reports. Organogenesis had a net margin of 1.14% and a return on equity of 1.81%. The company had revenue of $109.98 million during the quarter, compared to analyst estimates of $100.44 million. During the same period in the previous year, the business earned ($0.02) EPS. Organogenesis updated its FY 2024 guidance to EPS.

Organogenesis Stock Performance

Organogenesis stock traded up $0.75 during midday trading on Friday, reaching $3.03. 3,549,588 shares of the company traded hands, compared to its average volume of 919,585. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.80 and a quick ratio of 2.44. Organogenesis has a 12 month low of $1.96 and a 12 month high of $4.70. The firm has a market capitalization of $399.85 million, a price-to-earnings ratio of 75.75 and a beta of 1.60. The business has a 50 day moving average of $2.75 and a two-hundred day moving average of $3.08.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $5.00 price target on shares of Organogenesis in a research note on Friday, March 1st.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.